Digital Desk, Washington. US-based pharma company Pfizer and German company Bioentech’s joint corona vaccine have been found to be up to 95% effective in the third phase trial. The company claims that the vaccine worked well for the elderly. The company says that with this success, it can achieve emergency approval from the US Food and Drug Administration (USFDA).
Pfizer’s Phase 3 clinical trial began on 27 July. It consisted of 43,661 people. After the success of the trial, the vaccine will now go to the FDA for emergency approval in the third week of November. The vaccine is expected to be approved by the end of this year for high-risk populations. However this will happen only when everything goes according to planning. Pfizer and BioNotech say they can make 1.3 billion doses every year, but this is less than the world needs.
Pfizer had previously described the vaccine as 90 percent effective and said it was a big day for science and humanity. From the first set of results of the third phase of the trial, it has become clear that our vaccine is effective in fighting the corona virus. We are establishing a new dimension in vaccine discovery. This is the time when the whole world is in need of the corona virus vaccine. Pfizer and Biontech are the first companies to report the widespread use and successful results of the vaccine. The companies said they have not seen any serious security concerns so far.
The vaccine produces antibodies in the body to fight the corona virus and forms T-cells, another part of the immune system. According to preliminary findings, the virus-fighting ability develops in patients seven days after the second dose and 28 days after the first dose. However, there are questions about how long the resistance will last and what will be the effect on people of different age groups? The company has not given information about this yet. To save time, companies have already started manufacturing the vaccine before the vaccine will be effective.